相关实验视频
Updated: May 14, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
住院患者低血糖症的时间模式依赖于治疗
Wharton O Y Chan1, Paik Shia Lim2, Alcey Li Chang Ang3
1Programme in Emerging Infectious Disease, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.
Therapeutic advances in endocrinology and metabolism
|May 12, 2025
概括
住院低血糖症因糖尿病药物治疗时间而异. 硫尿素和基础胰岛素与夜间低血糖有关,而预混合胰岛素与晚间发作有关. 有针对性的监测可以降低风险.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 住院低血糖症是一个重大问题,对患者因素进行了广泛的研究.
- 现有的研究往往忽略了与低血糖事件相关的时间和特定的糖尿病药物.
研究的目的:
- 以一天的时间和相关的糖尿病药物来表征住院患者的低血糖症.
- 为基于药物类型的最佳监测策略提供见解.
主要方法:
- 在两个月内对425次低血糖症发作进行了回顾性观察研究.
- 发作被定义为毛细血管血糖 (CBG) <4 mmol/L.
- 分析包括时间框架:白天 (0801-1600),晚上 (1601-2359) 和晚上 (0000-0800).
主要成果:
- 硫基尿素 (31.8%) 和预混合胰岛素 (30.4%) 最常与低血糖相关.
- 基本胰岛素和硫氨酸尿素相关的低血糖症主要发生在夜间 (0000-0800).
- 预混合胰岛素相关低血糖症在晚上最常见 (1601-2359).
结论:
- 基于糖尿病药物治疗的低血糖症时间存在显著差异.
- 建议进行分层监测,包括针对特定药物的战略性凌晨3点CBG测试.
- 这种方法可以帮助减轻住院患者低血糖症的风险.
相关概念视频
Hypoglycemia and Glucagon
142
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
142
SBAR II: Application of SBAR
4.2K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
4.2K
Oral Hypoglycemic Agents: Glinides
111
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
111
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Insulin: Dosing Regimen and Adverse Effects
127
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
127
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K

